Our results not only contribute to a better understanding of ageing and the physiological function of prohibitins but also can provide valuable information for the development of therapeutic strategies to tackle prohibitin-associated diseases such as cancer, neurological, inflammatory, and metabolic diseases [11] as well as other age-related diseases. Here, PHB1 is linked to metabolic disease.